

Supporting Information

3-(Benzo[d]thiazol-2-yl)-4-aminoquinoline derivatives as novel scaffold topoisomerase I inhibitor *via* DNA intercalation: design, synthesis and antitumor activities

Jing-Mei Yuan[†], Nan-Ying Chen[†], Hao-Ran Liao, Guo-Hai Zhang, Xiao-Juan Li, Zi-Yu Gu, Cheng-Xue Pan*,
Dong-Liang Mo*, Gui-Fa Su*

State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, PR China

[†] These authors contributed equally to this work.

* Corresponding Authors: Professors Cheng-Xue Pan, Dong-Liang Mo, and Gui-Fa Su

Tel. & Fax: +86 773 3696862, Email: chengxuepan@163.com (C.-X. Pan);
moeastlight@gxnu.edu.cn (D.-L. Mo); gfysslglx@163.com (G.-F. Su)

Table of Contents

1. X-ray crystallography of compound 6i	2
2. Spectrum of UV-vis absorption and fluorescent emission profile for 5a	3
3. NMR and HRMS spectrum for compounds 5a–6n	4-30
4. HPLC spectrum of the target compounds.....	31-37

1. X-ray crystallography of compound **6i**




Fig. S1. Crystal structure diagram of compound **6i**.

Table S1

Some crystallographical data for compound **6i**

Empirical formula	C ₂₀ H ₁₉ ClN ₄ S
Formula weight	382.91
Temperature/K	296.15
Crystal system	monoclinic
Space group	P2 ₁ /n
a/Å, b/Å, c/Å	13.793 (5), 8.597 (3), 16.140 (5)
α/°, β/°, γ/°	90.00, 104.275 (5), 90.00
Volume/Å ³	1854.7 (11)
Z	4
ρ _{calc} /mg mm ⁻³	1.375
μ/mm ⁻¹	0.33
F (000)	804
Crystal size/mm ³	0.44 × 0.20 × 0.15
2θ range for data collection	3.48 to 52.74°
Index ranges	-17 ≤ h ≤ 17, -10 ≤ k ≤ 10, -20 ≤ l ≤ 20
Reflections collected	20774
Independent reflections	3791[R(int) = 0.0570]
Data/restraints/parameters	3791/0/237
Goodness-of-fit on F ²	1.026
Final R indexes [I > 2σ (I)]	R1 = 0.0592, wR2 = 0.1569
Final R indexes [all data]	R1 = 0.0900, wR2 = 0.1793
Largest diff. peak/hole/e·Å ⁻³	0.923/-0.470

2. Spectrum of UV-vis absorption and fluorescent emission profile for **5a**




Fig. S2. UV-vis absorption spectrum of **5a**










Fig. S3. Fluorescent emission spectrum of **5a**



3. NMR and HRMS spectrum for compounds 5a–6n








lhr091_140307170620 #2-B RT: 0.01-0.03 AV: 7 NL: 1.27E7
T: FTMS + p ESI Full ms [300.00-500.00]








13 #6-32 RT: 0.01-0.11 AV: 31 NL: 4.41E8
T: FTMS + p ESI Full ms [300.00-480.00]








151 #2-26 RT: 0.01-0.09 AV: 25 NL: 2.37E7
T: FTMS + p ESI Full ms [300.00-450.00]








53 #2-46 RT: 0.01-0.15 AV: 45 NL: 1.60E7
T: FTMS + p ESI Full ms [350.00-480.00]








168 #2-17 RT: 0.01-0.06 AV: 16 NL: 9.94E6
T: FTMS + p ESI Full ms [300.00-450.00]








lhr085 #1-6 RT: 0.01-0.02 AV: 6 NL: 1.15E7
T: FTMS + p ESI Full ms [300.00-440.00]








142 #3.23 RT: 0.01-0.08 AV: 21 NL: 6.96E6
T: FTMS + p ESI Full ms [100.00-450.00]








41_151012190004 #6-26 RT: 0.01-0.10 AV: 27 NL: 1.09E5
T: FTMS + p ESI Full ms [410.00-480.10]








lhr076_140307160749 #2-11 RT: 0.01-0.04 AV: 10 NL: 2.77E6
T: FTMS + p ESI Full ms [300.00-500.00]






55 #6-49 RT: 0.01-0.14 AV: 38 NL: 5.01E6
T: FTMS + p ESI Full ms [350.00-480.00]








95 #2 RT: 0.01 AV: 1 NL: 4.95E7



T: FTMS + p ESI Full ms [300.00-700.00]









45_151012195127 #62-41 RT: 0.01-0.14 AV: 40 NL: 1.19E9
T: FIMS +p ESI Full ms [370.00-410.10]








79-s #0-30 RT: 0.01-0.13 AV: 37 NL: 5.61E9
T: FTMS + p ESI Full ms [800.00-480.00]












141 #1-15 RT: 0.00-0.05 AV: 15 NL: 2.77E7
T: FTMS + p ESI Full ms [100.00-450.00]








lhr073 #3-11 RT: 0.01-0.04 AV: 9 NL: 1.14E8
T: FTMS + p ESI Full ms [100.00-500.00]








lhr092 #2-8 RT: 0.01-0.03 AV: 7 NL: 4.50E7
T: FTMS + p ESI Full ms [300.00-500.00]








152 #2-8 RT: 0.01-0.03 AV: 7 NL: 1.30E7
T: FTMS + p ESI Full ms [300.00-450.00]








158 #2-13 RT: 0.01-0.05 AV: 12 NL: 2.15E7
T: FTMS + p ESI Full ms [300.00-450.00]








169 #3-14 RT: 0.01-0.05 AV: 12 NL: 1.50E7
T: FTMS + p ESI Full ms [100.00-450.00]








lhr086 #2-11 RT: 0.01-0.04 AV: 10 NL: 4.31E6
T: FTMS + p ESI Full ms [300.00-500.00]








143 #2-17 RT: 0.01-0.06 AV: 16 NL: 8.07E6
T: FTMS + p ESI Full ms [300.00-450.00]






lhr077 #2-11 RT: 0.01-0.04 AV: 10 NL: 5.79E6
T: FTMS + p ESI Full ms [400.00-440.00]







96 #2-8 RT: 0.01-0.03 AV: 7 NL: 1.92E7
T: FTMS + p ESI Full ms [300.00-500.00]




4. The HPLC spectrum of the target compounds.




5a




5b




5c




5e




5f




5h




5i




5j




5l




5n




6a




6b




6c




6e




6f




6h




6i



6j



6l



6n